Brief: Surrozen Announces Safety, Pharmacodynamic And Liver Function Data For SZN-043
01/04/2024 17:16
April 1 (Reuters) - Surrozen Inc SRZN.O :
* SURROZEN ANNOUNCES SAFETY, PHARMACODYNAMIC AND LIVER
FUNCTION
DATA FOR SZN-043
* SURROZEN INC -PHASE 1A TRIAL DEMONSTRATED ACCEPTABLE
SAFETY AND
TOLERABILITY WITH NO REPORTED SERIOUS ADVERSE EVENTS
* SURROZEN INC -PHASE 1A DATA DEMONSTRATED TARGET
ENGAGEMENT, A
PHARMACODYNAMIC EFFECT AND EFFECTS ON LIVER FUNCTION
Source text for Eikon: ID:nGNX8m3kXx
Further company coverage: SRZN.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Surrozen
See all newsBrief: Surrozen Announces Closing Of Second Tranche Of March 2025 Private Placement For $95.1 Million
Surrozen, Inc. reports results for the quarter ended June 30 - Earnings Summary
Brief: Surrozen Q2 Operating Income USD -10.37 Million
Surrozen, Inc. expected to post a loss of $1.29 a share - Earnings Preview
Brief: Surrozen Q1 EPS USD -11.65